Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) - Net Assets
Based on the latest financial reports, Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) has net assets worth CN¥1.15 Billion CNY (≈ $167.89 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.91 Billion ≈ $278.76 Million USD) and total liabilities (CN¥757.69 Million ≈ $110.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Shaanxi Meibang Pharmaceutical Group Co 's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.15 Billion |
| % of Total Assets | 60.23% |
| Annual Growth Rate | 29.87% |
| 5-Year Change | 150.28% |
| 10-Year Change | N/A |
| Growth Volatility | 37.17 |
Shaanxi Meibang Pharmaceutical Group Co Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Shaanxi Meibang Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Shaanxi Meibang Pharmaceutical Group Co for the complete picture of this company's asset base.
Annual Net Assets for Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)
The table below shows the annual net assets of Shaanxi Meibang Pharmaceutical Group Co Ltd from 2017 to 2024. For live valuation and market cap data, see 605033 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.12 Billion ≈ $164.57 Million |
+0.94% |
| 2023-12-31 | CN¥1.11 Billion ≈ $163.04 Million |
+2.56% |
| 2022-12-31 | CN¥1.09 Billion ≈ $158.97 Million |
+12.35% |
| 2021-12-31 | CN¥966.95 Million ≈ $141.50 Million |
+115.18% |
| 2020-12-31 | CN¥449.37 Million ≈ $65.76 Million |
+21.24% |
| 2019-12-31 | CN¥370.63 Million ≈ $54.24 Million |
+34.10% |
| 2018-12-31 | CN¥276.37 Million ≈ $40.44 Million |
+53.18% |
| 2017-12-31 | CN¥180.43 Million ≈ $26.40 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shaanxi Meibang Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 677.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥501.56 Million | 44.60% |
| Common Stock | CN¥135.20 Million | 12.02% |
| Other Comprehensive Income | CN¥28.54 Million | 2.54% |
| Other Components | CN¥459.37 Million | 40.85% |
| Total Equity | CN¥1.12 Billion | 100.00% |
Shaanxi Meibang Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Shaanxi Meibang Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DINGDONG CAYMAN 2ADR/3 A
F:945
|
$459.79 Million |
|
Lotte Non-Life
KO:000400
|
$459.81 Million |
|
Hunan Hengguang Technology Co.Ltd.
SHE:301118
|
$459.89 Million |
|
Alandsbanken Abp B
HE:ALBBV
|
$459.95 Million |
|
Marimekko Oyj
HE:MEKKO
|
$459.62 Million |
|
Longxing Chemical Stock Co Ltd
SHE:002442
|
$459.56 Million |
|
Varex Imaging Corp
NASDAQ:VREX
|
$459.44 Million |
|
ProCredit Holding AG & Co KGaA
XETRA:PCZ
|
$459.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shaanxi Meibang Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,114,165,716 to 1,124,660,984, a change of 10,495,268 (0.9%).
- Net income of 36,859,267 contributed positively to equity growth.
- Dividend payments of 28,240,041 reduced retained earnings.
- Other comprehensive income increased equity by 6,863,108.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥36.86 Million | +3.28% |
| Dividends Paid | CN¥28.24 Million | -2.51% |
| Other Comprehensive Income | CN¥6.86 Million | +0.61% |
| Other Changes | CN¥-4.99 Million | -0.44% |
| Total Change | CN¥- | 0.94% |
Book Value vs Market Value Analysis
This analysis compares Shaanxi Meibang Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.60x to 2.82x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥2.00 | CN¥23.24 | x |
| 2018-12-31 | CN¥2.93 | CN¥23.24 | x |
| 2019-12-31 | CN¥3.71 | CN¥23.24 | x |
| 2020-12-31 | CN¥4.44 | CN¥23.24 | x |
| 2021-12-31 | CN¥7.15 | CN¥23.24 | x |
| 2022-12-31 | CN¥8.04 | CN¥23.24 | x |
| 2023-12-31 | CN¥8.32 | CN¥23.24 | x |
| 2024-12-31 | CN¥8.24 | CN¥23.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shaanxi Meibang Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.16%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.66x
- Recent ROE (3.28%) is below the historical average (16.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 33.93% | 14.51% | 0.83x | 2.82x | CN¥43.18 Million |
| 2018 | 21.47% | 13.53% | 0.75x | 2.12x | CN¥31.69 Million |
| 2019 | 20.57% | 14.79% | 0.77x | 1.80x | CN¥39.19 Million |
| 2020 | 17.52% | 13.85% | 0.72x | 1.75x | CN¥33.80 Million |
| 2021 | 13.00% | 14.93% | 0.58x | 1.51x | CN¥29.05 Million |
| 2022 | 13.36% | 16.01% | 0.58x | 1.44x | CN¥36.45 Million |
| 2023 | 5.17% | 8.23% | 0.41x | 1.52x | CN¥-53.86 Million |
| 2024 | 3.28% | 4.16% | 0.48x | 1.66x | CN¥-75.61 Million |
Industry Comparison
This section compares Shaanxi Meibang Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $4,801,976,162
- Average return on equity (ROE) among peers: 6.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) | CN¥1.15 Billion | 33.93% | 0.66x | $459.78 Million |
| Hubei Yihua Chemical Industry Co Ltd (000422) | $7.86 Billion | 11.02% | 2.77x | $2.69 Billion |
| Nanjing Red Sun Co Ltd (000525) | $3.98 Billion | 4.57% | 1.08x | $1.05 Billion |
| ADAMA Ltd (000553) | $21.08 Billion | 0.75% | 1.38x | $2.17 Billion |
| Grand Industrial Holding Co Ltd (000626) | $3.10 Billion | 7.17% | 1.46x | $693.17 Million |
| Sichuan Meifeng Chemical Industry Co Ltd (000731) | $1.81 Billion | 11.10% | 1.14x | $581.45 Million |
| Qinghai Salt Lake Industry Co.Ltd (000792) | $3.36 Billion | 24.18% | 0.70x | $30.42 Billion |
| Asia Potash International Investment Guangzhou Co Ltd (000893) | $413.91 Million | 8.29% | 1.31x | $7.31 Billion |
| Hubei Xinyangfeng Fertilizer Co Ltd (000902) | $402.47 Million | -12.08% | 2.18x | $2.80 Billion |
| Sichuan Lutianhua Co Ltd (000912) | $6.26 Billion | 5.87% | 0.66x | $1.12 Billion |
| Guangxi Hechi Chemical Co Ltd (000953) | $-249.80 Million | 0.00% | 0.00x | $374.49 Million |
About Shaanxi Meibang Pharmaceutical Group Co Ltd
Shaanxi Meibang Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, sale, and agricultural technology promotion, and service of pesticide products in China and internationally. The company offers pesticides, fungicides, herbicides, plant growth regulators, fertilizers, and microbial fertilizers. It is also involved in sale of agricu… Read more